Clinical trial • Not applicable • Other

Ketamine hydrochloride for Bariatric surgery

Not applicable trial of Ketamine hydrochloride for Bariatric surgery.

Overview

Trial Therapeutic Area
Other
Trial Disease
Bariatric surgery
Trial Stage
Not applicable
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
18-11-2024
First CTIS Authorization Date
20-11-2024

Trial design

Conventional anesthesia (comparator; not specified drug, dose, or schedule)-controlled Not applicable trial across 1 site in Spain.

Comparator
Conventional anesthesia (comparator; not specified drug, dose, or schedule)
Target Sample Size
72

Eligibility

Recruits 72 No vulnerable population selected. Participants must give informed consent (patients aged 18 or over)..

Vulnerable Population
No vulnerable population selected. Participants must give informed consent (patients aged 18 or over).

Inclusion criteria

  • {"criterion_text":"- Patients aged 18 or over"}
  • {"criterion_text":"- Patients pending laparoscopic vertical gastrectomy for bariatric surgery."}
  • {"criterion_text":"- Give informed consent"}

Exclusion criteria

  • {"criterion_text":"- Advanced heart block (grade 2 or 3 in the absence of a pacemaker)."}
  • {"criterion_text":"- Preoperative renal dysfunction, estimated through the preoperative GFR rate (creatinine clearance < 50ml/min)."}
  • {"criterion_text":"- Liver failure"}
  • {"criterion_text":"- Hypersensitivity to gabapentin, lidocaine, dexmedetomidine, ketamine, NSAIDs, paracetamol or Magnesium Sulfate."}
  • {"criterion_text":"- Myasthenia gravis"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- To evaluate the effect of Opioid-Free Anesthesia on the Arterial Oxygen Pressure/Inspired Fraction of Oxygen (PaO2/FiO2) ratio during the first 6 postoperative hours in comparison with conventional anesthesia.","definition_or_measurement_approach":"Measurement of the Arterial Oxygen Pressure/Inspired Fraction of Oxygen (PaO2/FiO2) ratio during the first 6 postoperative hours; comparison between Opioid-Free Anesthesia and conventional anesthesia."}

Recruitment

Planned Sample Size
72
Recruitment Window Months
17
Consent Approach
Written informed consent obtained from participants (patients aged 18 or over). A subject information and informed consent form document is listed for publication. Spanish translations of trial documents are available.

Geography

Total Number Of Sites
1
Total Number Of Participants
72

Spain

Earliest CTIS Part Ii Submission Date
18-11-2024
Latest Decision Or Authorization Date
20-11-2024
Processing Time Days
2
Number Of Sites
1
Number Of Participants
72

Sites

Site Name
Fundacion Publica Andaluza Para La Investigacion De Malaga En Biomedicina Y Salud
Department Name
Anestesia y Reanimacion
Contact Person Name
Alfredo Malo
Contact Person Email
elvira.bonilla@ibima.eu
Number Of Participants
72

Sponsor

Primary sponsor

Full Name
Fundacion Publica Andaluza Para La Investigacion De Malaga En Biomedicina Y Salud
Organisation Type
Laboratory/Research/Testing facility
Country Of Registered Address
Spain

Third parties

  • {"country":"Spain","full_name":"Fundacion Publica Andaluza Para La Investigacion De Malaga En Biomedicina Y Salud","duties_or_roles":"sponsorDuties code 5","organisation_type":"Laboratory/Research/Testing facility"}

Investigational products

Investigational Product Name
KETOLAR 50 mg/ml solución inyectable.
Active Substance
Ketamine hydrochloride
Modality
Small molecule
Routes Of Administration
Intravenous administration
Route
Intravenous administration
Authorisation Status
Marketing authorisation in Spain (marketingAuthNumber 47.034; prodAuthStatus 2)
Maximum Dose
maxTotalDoseAmount 1.1 % (V/V) (as listed in product attributes)

Related trials

Other published trials that may interest you.